New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
10:00 EDTETFC, SMI, XOOM, POT, MTH, HON, ATLS, HAFC, SALE, BTU, MRK, EIX, AGI, KSU, FMBI, PB, MHK, MTGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alamos Gold (AGI) upgraded to Outperform from Sector Perform at RBC Capital... Atlas Energy (ATLS) upgraded to Outperform from Neutral at RW Baird... E-Trade (ETFC) upgraded to Outperform from Market Perform at JMP Securities... Edison International (EIX) upgraded to Hold from Underperform at Jefferies... Honeywell (HON) upgraded to Buy from Hold at Lagenberg... MGIC Investment (MTG) upgraded to Outperform from Market Perform at JMP Securities... Merck (MRK) upgraded to Overweight from Underweight at Morgan Stanley... Meritage Homes (MTH) upgraded to Overweight from Equal Weight at Barclays... Mohawk (MHK) upgraded to Overweight from Neutral at JPMorgan... Peabody (BTU) upgraded to Neutral from Underperform at BofA/Merrill... Potash (POT) upgraded to Outperform from Market Perform at Raymond James... Prosperity Bancshares (PB) upgraded to Outperform from Market Perform at BMO Capital... RetailMeNot (SALE) upgraded to Buy from Neutral at Goldman... Xoom (XOOM) upgraded to Strong Buy from Market Perform at Raymond James... First Midwest (FMBI) upgraded to Outperform from Market Perform at Fig Partners... Hanmi Financial (HAFC) upgraded to Outperform from Market Perform at Keefe Bruyette... Semiconductor Manufacturing (SMI) upgraded to Buy from Sell at UBS... Kansas City Southern (KSU) upgraded to Neutral from Underperform at Buckingham.
News For AGI;ATLS;ETFC;EIX;HON;MTG;MRK;MTH;MHK;BTU;POT;PB;SALE;XOOM;FMBI;HAFC;SMI;KSU From The Last 14 Days
Check below for free stories on AGI;ATLS;ETFC;EIX;HON;MTG;MRK;MTH;MHK;BTU;POT;PB;SALE;XOOM;FMBI;HAFC;SMI;KSU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 15, 2014
09:16 EDTPOTOn The Fly: Pre-market Movers
Subscribe for More Information
09:07 EDTPOTPotash volatility expected to move on speculation of being target
Subscribe for More Information
08:23 EDTMRKLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTMRKLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:46 EDTPOTPotash Corp. speculated to be targeted again by BHP Billiton, Globe & Mail says
Subscribe for More Information
06:32 EDTMRKPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
18:00 EDTMRKU.S. FDA approves Merck's GRASTEK
Subscribe for More Information
10:02 EDTXOOMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:25 EDTXOOMXoom initiated with a Buy at Buckingham
Subscribe for More Information
06:08 EDTMRKMerck volatility elevated into Q1 and outlook
Subscribe for More Information
April 11, 2014
12:42 EDTETFCOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:02 EDTETFCE-Trade upgraded to Overweight from Underweight at Barclays
Barclays upgraded E-Trade two notches to Overweight from Underweight based on valuation and an improved capital profile. Price target raised to $24 from $20.
05:22 EDTMRKMerck says Hepatitis C combination therapy shows antiviral activity
Subscribe for More Information
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
17:04 EDTKSUKansas City Southern initiated with an Underperform at Macquarie
Target $100.
09:37 EDTMRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
09:06 EDTETFCSEC still struggling for data, slow to move on HFT, Bloomberg says
Subscribe for More Information
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-na´ve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use